Insight

Nelson Dusetti

Jan 6, 2025, 10:15

Nelson Dusetti: New therapeutic avenues for new therapeutic avenues for improving PDAC treatment

Nelson Dusetti, Research Director at INSERM, shared a post on LinkedIn, about a recent paper by Emilie Jaune-Pons et al. published in JCI Insight.

“It was a true pleasure to contribute to this work, and I am especially glad to have been involved in this important collaboration with Emilie Jaune-Pons, Christopher Pin from Western University London, Ontario, Canada, and Raul Urrutia, and Gwen Lomberk MCW Department of Surgery, Division of Research, Medical College of Wisconsin, USA.

The discoveries in this study, recently published in JCI Insight, offer new therapeutic avenues for targeting the tumor microenvironment and improving PDAC treatment strategies.

This study provides valuable insights into how EZH2, a key member of the Polycomb Repressor Complex, regulates tumor initiation and progression in pancreatic ductal adenocarcinoma (PDAC), one of the most aggressive forms of cancer. Their research highlights how EZH2 expression in acinar cells helps restrict PDAC initiation and progression by modulating both the tumor microenvironment and acinar cell differentiation.

This work underscores the growing importance of epigenomics in pancreatic cancer, a field that continues to gain prominence in cancer research.”

“EZH2 deletion does not impact acinar regeneration but restricts progression to pancreatic cancer in mice.”

Authors: Emilie Jaune-Pons, Xiaoyi Wang, Fatemeh Mousavi, Gwen Lomberk, Christopher Pin et al.

Nelson Dusetti: New therapeutic avenues for new therapeutic avenues for improving PDAC treatment

More posts featuring Nelson Dusetti.

Nelson Dusetti is the Scientific Director of the company Predicting Med (CSO) and Chair of TRANSLATE-IT CRCM. He is also the research director at INSERM. He is the Head of the Department of Translational Research and Innovative Therapies at CRCM.